Dear colleagues,
I would like to invite you to the lecture by Romana Hendrychová called "Multiplex immunofluorescence using the Orion platform (Rarecyte): challenges and advantages". The lecture will be on Wednesday June 11, 2025 at 9AM in the room 1.09 at IMTM.
Abstract
Cyclic multiplex immunohistochemistry techniques have undergone significant technological advancements in recent years. Several sophisticated platforms now allow simultaneous application of all antibodies in a panel followed by single-round multispectral imaging, significantly reducing processing time and facilitating digitalimage analysis. One such system is the Orion platform by RareCyte, which enables detection of up to 20 biomarkers per staining cycle using 18 fluorescence channels. This capacity meets the demands of high-dimensional analysis required for detailed phenotyping of immune and tumor populations, characterization ofthe tissue microenvironment, and investigation of therapeutic mechanisms. The ability to combineimmunofluorescence with H&E staining on the same tissue section provides essential spatial and morphologicalcontext. Whole-slide imaging further enhances statistical robustness and supports compliance with regulatorystandards, making the technology valuable for both clinical research and diagnostic applications.
At the Institute of Clinical and Molecular Pathology, Faculty of Medicine, Palacký University Olomouc, theOrion system was provided on a temporary basis for testing. As part of this collaboration, the device wassuccessfully implemented, and three antibody panels were developed for breast cancer, colorectal cancer, and pancreatic cancer. These panels included biomarkers such as CD3e, CD8a, CD68, CD163, E-cadherin, FAP, FOXP3, TIGIT, GLUT1, B4GALT6, CD15, Ki-67, PD-L1, Pan-CK, vimentin, SMA, among others. Digital analysis of the acquired datasets is currently underway, and a new panel specific for myelodysplastic syndrome is in development.